Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar

Table 2 Classification of treatment outcome

		Treatment group
Treatment outcome		CQ		AQ		SP		AQ+SP		AQ+AS
14-day follow-up
ETF (%)		4/39 (10.3)		0/38 (0)		0/38 (0)		0/81 (0)*		0/80 (0)*
LCF (%)	OTF (%)	7/39 (17.9)	14/39 (35.9)	0/38 (0)*	0/38 (0)	0/38 (0)*	1/38 (2.6)	0/81 (0)*	1/81 (1.2)	0/80 (0)*	0/80 (0)
LPF (%)		3/39 (7.7)		0/38 (0)		1/38 (2.6)		1/81 (1.2)		0/80 (0)
ACPR (%)		25/39 (64.1)		38/38 (100)*		37/38 (97.4)*		80/81 (98.8)*		80/80 (100)*
28-day follow-up non adjusted (PCR-uncorrected)
ETF (%)		4/36 (11.1)		0/36 (0)		0/38 (0)		0/79 (0)*		0/76 (0)*
LCF (%)	OTF (%)	9/36 (25.0)	20/36 (55.5)	3/36 (8.3)	5/36 (13.9)	0/38 (0)*	2/38 (5.2)	2/79 (2.5)*	4/79 (5.0)	3/76 (3.9)*	12/76 (15.7)
LPF (%)		7/36 (19.4)		2/36 (5.6)		2/38 (5.2)		2/79 (2.5)*		9/76 (11.8)
ACPR (%)		16/36 (44.5)		31/36 (86.1)*		36/38 (94.8)*		75/79 (95.0)*		64/76 (84.3)*
28-day follow-up adjusted (PCR-corrected)
New infections (%)		4/36 (11.1)		4/36 (11.1)		1/38 (2.6)		1/79 (1.2)**		6/76 (7.9)
ETF (%)		4/36 (11.1)		0/36 (0)		0/38 (0)		0/79 (0)*		0/76 (0)*
LCF (%)	OTF (%)	7/36 (19.4)	13/36 (44.4)	1/36 (2.8)	1/36 (2.8)	0/38 (0)	1/38 (2.6)	1/79 (1.3)*	3/78 (3.8)	1/76 (1.3)*	6/76 (7.9)
LPF (%)		5/36 (13.9)		0/36 (0)*		1/38 (2.6)		2/79 (2.5)*		5/76 (6.6)
ACPR (%)		20/36 (55.6)		35/36 (97.2)*		37/38 (97.4)*		76/79 (96.2)*		70/76 (92.1)*

Data presented are cumulative, failures up to day 14 of follow-up are also considered in the calculation of day 28 failure rates.
Percentages are rounded to achieve totals of 100%.
CQ, Chloroquine; AQ, amodiaquine; SP, Sulphadoxine-pyrimethamine; AS, artesunate ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure; ACPR, adequate clinical and parasitological response.
* Significant difference to CQ group (P < 0.05); ** Significant difference to CQ and AQ groups (P < 0.05).

ISSN: 1475-2875